Delivering Sight.
Without a Needle.

Non-invasive Ultrasound
Ocular Drug Delivery Platform

MeticTouch® is a non-invasive ultrasound ocular drug delivery platform enabling transscleral delivery of therapeutic molecules to the posterior segment target compartments - validated by completed preclinical programme and ready for clinical translation.

 

 

 

The Problem
The Problem

Millions of Injections.
Every Year. Into the Eye.

  • Requires administration by trained professional in a controlled clinical setting
  • Repeated clinic visits can add to the long-term burden of care
  • Anti-VEGF treatment often requires recurrent intervention over time
  • Needle-based procedures may contribute to anxiety and make treatment persistence more challenging

 

 

 

The Solution

Our MeticTouch Platform

Acoustic Streaming

Low-frequency ultrasound generates acoustic streaming and microstreaming within the ocular fluid, creating transient, reversible pathways through the scleral tissue that enhance macromolecule transport.

Defined Safety Window

At the intended clinical ultrasound intensity, preclinical studies show minimal, transient findings with no meaningful damage to retina, choroid or ciliary body. Head-to-head NHP data demonstrated superior local tolerability versus IVT, supporting readiness for clinical translation.

Proven Anatomic Efficacy

Across multiple species and anti-VEGF molecules, nonclinical studies have shown that MeticTouch® delivers posterior-segment drug levels sufficient to produce anatomic efficacy comparable to standard intravitreal injection, with a clean local safety profile.

30 Seconds Treatment

Treatment
Comparison

Non-invasive solutions
MeticTouch® highly reduces risks and complications in treatment procedures, compared to traditional eye injections.

Traditional eye injection

Problems of Traditional Eye injections:

  • Current first-line posterior drug delivery focus on invasive injections
  • Lack of emphasis on the improvement of patient experience in current research field
  • Intravitreal injections are classified as surgical procedures in key markets and require sterile technique, monitoring, and carry procedural risks
  • Up to 50% of patients opting out of injection treatments1
MeticTouch non-invasive delivery

Solutions provided by MeticTouch®:

  • A non-invasive alternative to traditional eye injections
  • Compatible with a wide range of anti-VEGF and biologic APIs
  • Designed to reduce procedural risks associated with needle-based delivery
  • Patient-centered approach intended to support treatment adherence

 

 

Patient

  • Needle-free administration
  • Safe and Effective Treatment
  • Treatment Adherence

Clinician

  • Streamlined workflow
  • Eliminates injection-associated risks
  • Improve patient compliance

Pharma Partner

  • New administration-route opportunity
  • Potential portfolio differentiation
  • Partner-defined collaboration
Therapeutic Applications

Target
Disease Area

Broad Therapeutic Applicability
MeticTouch® is designed for posterior segment diseases where injection is currently required, with validated compatibility across a range of therapeutic molecules.

It is a common condition that damages the central part of the retina, affecting detailed vision needed for reading and recognising faces. It typically begins after age 50.

  • Population 196 million affected globally2
  • Current Delivery Standard Intravitreal Injection (IVT)
  • Representative Molecules Evaluated
    Aflibercept Ranibizumab Faricimab

MeticTouch® enables sustained delivery of anti-VEGF biologics to the posterior segment without intravitreal injection.

Diabetic Macular Edema (DME) is a serious complication of diabetic retinopathy in which fluid accumulates in the macula, leading to vision impairment. It is one of the leading causes of vision loss among people with diabetes.

  • Population ~750,000 patients in the US3
  • Current Treatment Options Intravitreal Injection (IVT), Laser treatment
  • Representative Molecules Evaluated
    Aflibercept Ranibizumab Faricimab

MeticTouch® is validated compatible with Ranibizumab, Aflibercept and Faricimab in preclinical models.

Diabetic retinopathy is a progressive microvascular retinal complication of diabetes. In its advanced stages, abnormal blood-vessel growth and retinal damage can threaten vision and may require repeated intervention.

  • Population 146 million patients worldwide4
  • Current Treatment Options Intravitreal Injection (IVT), Surgery
  • Representative Molecules Evaluated
    Bevacizumab Aflibercept Ranibizumab

MeticTouch® is preclinically proven compatible with next-generation bispecific antibodies including Faricimab.

Rare retinal diseases are generally genetic or autoimmune conditions that progressively retina damage and severe vision loss. While there is no universal cure, ongoing advancements in gene therapy and stem cell research offer promising new pathways for treatments.

  • Population 5.5 million patients worldwide5
  • Emerging Modalities Gene Therapy, Biologics

MeticTouch® platform's non-invasive transscleral pathway offers a compelling alternative for large-molecule gene therapy vectors targeting the retinal pigment epithelium

Project Status

Trial-Ready
Platform

MeticTouch® is fully prepared for clinical translation, with all preclinical evaluations completed, quality systems in place, and clinical-grade units manufactured.

  1. 2018 - 2021
    Proof of Concept

    Translation of university research into viable product and protocol

  2. 2024
    Preclinical Validations

    Studies in safety, efficacy, and bioavailability across multiple species and molecules

  3. 2025
    Product Industrialisation

    Device development, workflow optimisation, and regulatory prep.

  4. 2026
    Compliance & FIH Units

    Quality systems in place and clinical units ready

  5. 2026 - 2027
    First-in-Human

    FIH clinical trial initiation

Ready to Explore a Partnership?

Evaluate MeticTouch® with your molecule. Request the preclinical data summary, or contact our BD team to plan an NDA-enabled technical review.

Learn More Partnering with Us

Disclaimer: The graphics on this page depict a reference Mechanism of Action (MOA) created to explain the underlying principles of our proprietary technology. These visuals are abstract models and are not intended to represent actual biological responses, precise physiological scales, or predictable clinical results. Individual patient outcomes will differ. Nothing on this website constitutes medical advice or a guarantee of treatment performance.